JPMorgan Chase & Co. Sells 19,675 Shares of Vanda Pharmaceuticals Inc. (VNDA)

JPMorgan Chase & Co. lessened its stake in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 6.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 291,095 shares of the biopharmaceutical company’s stock after selling 19,675 shares during the quarter. JPMorgan Chase & Co. owned approximately 0.56% of Vanda Pharmaceuticals worth $6,681,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the company. Virginia Retirement Systems ET AL acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at about $754,000. State of Wisconsin Investment Board lifted its stake in shares of Vanda Pharmaceuticals by 58.5% in the second quarter. State of Wisconsin Investment Board now owns 52,300 shares of the biopharmaceutical company’s stock valued at $996,000 after purchasing an additional 19,300 shares during the period. Rhumbline Advisers lifted its stake in shares of Vanda Pharmaceuticals by 22.2% in the second quarter. Rhumbline Advisers now owns 51,551 shares of the biopharmaceutical company’s stock valued at $982,000 after purchasing an additional 9,365 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Vanda Pharmaceuticals by 4.8% in the second quarter. Bank of New York Mellon Corp now owns 214,370 shares of the biopharmaceutical company’s stock valued at $4,084,000 after purchasing an additional 9,796 shares during the period. Finally, Strs Ohio lifted its stake in shares of Vanda Pharmaceuticals by 9.7% in the second quarter. Strs Ohio now owns 47,500 shares of the biopharmaceutical company’s stock valued at $904,000 after purchasing an additional 4,200 shares during the period. Institutional investors own 99.33% of the company’s stock.

Shares of VNDA opened at $26.24 on Friday. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -74.97, a price-to-earnings-growth ratio of 3.56 and a beta of 0.87. Vanda Pharmaceuticals Inc. has a 12-month low of $13.75 and a 12-month high of $33.44.



Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.18. The company had revenue of $49.13 million during the quarter, compared to analysts’ expectations of $49.44 million. Vanda Pharmaceuticals had a net margin of 7.06% and a return on equity of 5.88%. The firm’s quarterly revenue was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.03) earnings per share. Equities analysts expect that Vanda Pharmaceuticals Inc. will post 0.21 EPS for the current year.

Several analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of Vanda Pharmaceuticals in a research note on Thursday, November 8th. They issued a “buy” rating and a $26.00 price objective for the company. Zacks Investment Research cut shares of Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, November 7th. ValuEngine upgraded shares of Vanda Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 10th. Stifel Nicolaus raised their price objective on shares of Vanda Pharmaceuticals from $36.00 to $44.00 and gave the company a “buy” rating in a research note on Tuesday, December 11th. Finally, Oppenheimer reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, December 3rd. Three research analysts have rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $38.38.

TRADEMARK VIOLATION NOTICE: “JPMorgan Chase & Co. Sells 19,675 Shares of Vanda Pharmaceuticals Inc. (VNDA)” was reported by Dakota Financial News and is the sole property of of Dakota Financial News. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://dakotafinancialnews.com/2018/12/16/jpmorgan-chase-co-sells-19675-shares-of-vanda-pharmaceuticals-inc-vnda.html.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.

Read More: Growth Stocks, What They Are, What They Are Not

Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply